APA (7th ed.) Citation

RS, F., K, B., I, B., R, P., T, P., M, S., . . . J, E. (2020). Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast cancer research and treatment, 183(2), 419. https://doi.org/10.1007/s10549-020-05755-7

Chicago Style (17th ed.) Citation

RS, Finn, et al. "Overall Survival Results from the Randomized Phase 2 Study of Palbociclib in Combination with Letrozole Versus Letrozole Alone for First-line Treatment of ER+/HER2- Advanced Breast Cancer (PALOMA-1, TRIO-18)." Breast Cancer Research and Treatment 183, no. 2 (2020): 419. https://doi.org/10.1007/s10549-020-05755-7.

MLA (9th ed.) Citation

RS, Finn, et al. "Overall Survival Results from the Randomized Phase 2 Study of Palbociclib in Combination with Letrozole Versus Letrozole Alone for First-line Treatment of ER+/HER2- Advanced Breast Cancer (PALOMA-1, TRIO-18)." Breast Cancer Research and Treatment, vol. 183, no. 2, 2020, p. 419, https://doi.org/10.1007/s10549-020-05755-7.